Clinicopathological indices to predict hepatocellular carcinoma molecular classification

Liver International

Volumn 36, Issue 1, 2016, Pages 108-118

  Tan, Poh Seng ^a,b   Nakagawa, Shigeki ^a   Goossens, Nicolas ^a,c   Venkatesh, Anu ^a   Huang, Tiangui ^a   Ward, Stephen C ^a   Sun, Xiaochen ^a   Song, Won Min ^a   Koh, Anna ^a   Canasto Chibuque, Claudia ^a   Deshmukh, Manjeet ^a   Nair, Venugopalan ^a   Mahajan, Milind ^a   Zhang, Bin ^a   Fiel, Maria Isabel ^a   Kobayashi, Masahiro ^d   Kumada, Hiromitsu ^d   Hoshida, Yujin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d TORANOMON HOSPITAL   (Japan)

Author keywords

Clinical diagnostic; Gene expression; Histopathology; Molecular subclass; Predictive index

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 4; CATENIN BETA 1; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; COLLAGEN TYPE 1A2; COLLAGEN TYPE 3; COLLAGEN TYPE 3A1; COLLAGEN TYPE 6A2; CYTOKERATIN 19; DECARBOXYPROTHROMBIN; EPITHELIAL CELL ADHESION MOLECULE; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; K RAS PROTEIN; LYVE1 PROTEIN; MOLECULAR MARKER; MYC PROTEIN; ONCOPROTEIN; RAF PROTEIN; STROMAL CELL DERIVED FACTOR 1; SURVIVIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; WNT PROTEIN; YAP PROTEIN; BMP4 PROTEIN, HUMAN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER CLASSIFICATION; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PREDICTION; TRANSCRIPTOMICS; AMINO ACID SEQUENCE; CANCER GRADING; CLASSIFICATION; DRUG DEVELOPMENT; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; LIVER TUMOR; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PROGNOSIS;

AGED; ALPHA-FETOPROTEINS; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BONE MORPHOGENETIC PROTEIN 4; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; DRUG DISCOVERY; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KERATIN-19; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM GRADING; PROGNOSIS;

EID: 84933557723     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12889     Document Type: Article

References (59)

1. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virusinduced hepatocellular carcinoma. J Hepatol 2014; 60: S79–90.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.
3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised,double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34.
4. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma:reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072–9.
5. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385–92.
6. Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013; 23: 1422–33.
7. Turato C, Vitale A, Fasolato S, et al. SERPINB3 is associated with TGF-beta1 and cytoplasmic beta-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer 2014; 110: 2708–15.
8. Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2015; 60: S79–90.
9. Giannelli G, Villa E, Lahn M. Transforming growth factorbeta as a therapeutic target in hepatocellular carcinoma. Cancer Res 2014; 74: 1890–4.
10. Zhu AX, Gold PJ, El-Khoueiry AB, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013; 19: 920–8.
11. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma:a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55–63.
12. Hong Y, Peng Y, Guo ZS, et al. Epitope-optimized alphafetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology 2014; 59: 1448–58.
13. Finn RS, Aleshin A, Dering J, et al. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 2013; 57: 1838–46.
14. Deshmukh M, Hoshida Y. Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma. Hepatology 2013; 58: 2207.
15. Fitamant J, Kottakis F, Benhamouche S, et al. YAP inhibition restores hepatocyte differentiation in advanced HCC leading to tumor regression. Cell Rep 2015; 10: S2211–1247.
16. Easl-Eortc. EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.
17. Kojima K, April C, Canasto-Chibuque C, et al. Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS ONE 2014; 9: e86961.
18. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592–609.
19. Goodman ZD. Neoplasms of the liver. Mod Pathol 2007; 20(Suppl 1): S49–60.
20. Macsween RNM, Burt AD, Portmann B, Ferrell LD,Sciencedirect (Online Service). MacSween’s Pathology of the Liver, 6th edn. Edinburgh: Churchill Livingstone, 2011; 1 online resource (1 v.).
21. Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System, 4th edn. Lyon: International Agency for Research on Cancer, 2010.
22. Wu PC, Lai CL, Lam KC, Lok AS, Lin HJ. Clear cell carcinoma of liver. An ultrastructural study. Cancer 1983; 52: 504–7.
23. Audisio RA, Bombelli L, Lombardi L, Andreola S. A clinico-pathologic study of clear-cell hepatocellular carcinoma. Tumori 1987; 73: 389–95.
24. Yang SH, Watanabe J, Nakashima O, Kojiro M. Clinicopathologic study on clear cell hepatocellular carcinoma. Pathol Int 1996; 46: 503–9.
25. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010; 34: 1630–6.
26. Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch Pathol Lab Med 2013; 137: 961–6.
27. Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M. Hepatocellular carcinoma with steatohepatitic features:a clinicopathological study of Japanese patients. Histopathology 2014; 64: 951–62.
28. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462–503.
29. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
30. Unitt E, Marshall A, Gelson W, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 246–53.
31. Wood LD, Heaphy CM, Daniel HD, et al. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol 2013; 26: 1586–93.
32. Ikeda T, Seki S, Maki M, et al. Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. Pathol Int 2003; 53: 450–6.
33. Hoshida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma:recent advancements. Semin Liver Dis 2010; 30: 35–51.
34. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545–50.
35. Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 2013; 153: 707–20.
36. Song WM, Di Matteo T, Aste T. Nested hierarchies in planar graphs. Discrete Appl Math 2011; 159: 2135–46.
37. Song WM, Di Matteo T, Aste T. Building complex networks with Platonic solids. Phys Rev E Stat Nonlin Soft Matter Phys 2012; 85(4 Pt 2): 046115.
38. Tran LM, Zhang B, Zhang Z, et al. Inferring causal genomic alterations in breast cancer using gene expression data. BMC Syst Biol 2011; 5: 121.
39. Stinchcombe TE. Recent advances in the treatment of non-small cell and small cell lung cancer. F1000prime Rep 2014; 6: 117.
40. Salomao M, Remotti H, Vaughan R, et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012; 43: 737–46.
41. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667–76.
42. Boyault S, Rickman DS, De Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42–52.
43. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779–88.
44. Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol 2014; 61: 1088–96.
45. Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080–5.
46. Prins GS, Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation 2008; 76: 641–59.
47. Mehta V, Schmitz CT, Keil KP, et al. Beta-catenin (CTNNB1) induces Bmp expression in urogenital sinus epithelium and participates in prostatic bud initiation and patterning. Dev Biol 2013; 376: 125–35.
48. Ding BS, Cao Z, Lis R, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 2014; 505: 97–102.
49. Hong F, Tuyama A, Lee TF, et al. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology 2009; 49: 2055–67.
50. Chen Y, Huang Y, Reiberger T, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014; 59: 1435–47.
51. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758–67.
52. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725–34.
53. European Association for the Study of the Liver. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.
54. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995–2004.
55. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2010; 2: 14 ps2.
56. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29: 502–10.
57. Bruix J, Sherman M. Management of hepatocellular carcinoma:an update. Hepatology 2011; 53: 1020–2.
58. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 2013; 178: 38–45.
59. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656–65.